New combo therapy may delay prostate cancer's return
NCT ID NCT01786265
First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times
Summary
This study tests whether adding abiraterone and prednisone to standard hormone therapy works better than hormone therapy alone for men whose prostate cancer has come back after surgery or radiation. About 310 men will receive either hormone therapy or hormone therapy plus abiraterone and prednisone. The goal is to see which approach keeps PSA levels low for longer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can surgery boost control of spread prostate cancer?
- Can a better scan sharpen radiation for prostate cancer?
- Hormone therapy showdown: can an oral pill beat the shot for prostate cancer patients?
- Can tracking tumor movement during radiation make treatment more precise?
- Can a single small incision preserve sexual function after prostate cancer surgery?
- Can a shorter course of radiation tame prostate cancer with fewer side effects?